AR073544A1 - Proceso para la preparacion de pramlintida - Google Patents

Proceso para la preparacion de pramlintida

Info

Publication number
AR073544A1
AR073544A1 ARP090103394A ARP090103394A AR073544A1 AR 073544 A1 AR073544 A1 AR 073544A1 AR P090103394 A ARP090103394 A AR P090103394A AR P090103394 A ARP090103394 A AR P090103394A AR 073544 A1 AR073544 A1 AR 073544A1
Authority
AR
Argentina
Prior art keywords
asn
thr
ser
pro
leu
Prior art date
Application number
ARP090103394A
Other languages
English (en)
Inventor
Jin Guo Ding
Tsung Yu Hsiao
Original Assignee
Scinopharm Taiwan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Taiwan Ltd filed Critical Scinopharm Taiwan Ltd
Publication of AR073544A1 publication Critical patent/AR073544A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicacion 1: Un proceso para la preparacion de pramlintida de formula (1): Lys-[Cys-Asn-Thr-AIa-Thr-Cys]-Ala-Thr-Gln-Arg-Leu-AIa-Asn-Phe- Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 caracterizado porque comprende: (a) hacer reaccionar un péptido de cadena lateral protegida de formula (2): P1-Thr(P2)-Asn(P2)-Val-GIy-Ser(P2)-Asn(P2)-Thr(P2)-OH donde P1 y P2 son grupos protectores, con H-Tyr(P2)-NH2 para dar un péptido de cadena lateral protegida de formula (3) P1-Thr(P2)-Asn(P2)-Val-Gly-Ser(P2)-Asn(P2)-Thr(P2)-Tyr(P2)-NH2; (b) eliminar el grupo protector terminal P1 y hacer reaccionar con un péptido de cadena lateral protegida de formula (4) P1-Ser(P2)-Asn(P2)-Asn(P2)-Phe-Gly-Pro-Ile-Leu-Pro-Pro-OH donde P1 y P2 son como se han definido, para dar un péptido de cadena lateral protegida de formula (5) P-Ser(P2)-Asn(P2)-Asn(P2)-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr(P2)-Asn(P2)-Val-Gly-Ser(P2)-Asn(P2)-Thr(P2)-Tyr(P2)-NH2; (c) eliminar el grupo protector terminal P y hacer reaccionar con un péptido de cadena lateral protegida de formula (6) P1-Thr(P2)-Gln(P2)-Arg(P2)-Leu-Ala-Asn(P2)-Phe-Leu-Val-His(P2)-Ser(P2)-OH donde P1 y P2 son como se han definido, para dar un péptido de cadena lateral protegida de formula (7) P1-Thr(P2)-Gln(P2)-Arg(P2)-Leu-AIa-Asn(P2)-Phe-Leu-Val-His(P2)-Ser(P2)-Ser(P2)-Asn(P2)-Asn(P2)-Phe-GIy-Pro-Ile-Leu-Pro-Pro-Thr(P2)-Asn(P2)-Val-Gly-Ser(P2)-Asn(P2)-Thr(P2)-Tyr(P2)-NH2; (d) eliminar el grupo protector terminal P y hacer reaccionar un péptido de cadena lateral protegida de formula (8) P1-Lys(P2)-[Cys-Asn(P2)-Thr(P2)-AIa-Thr(P2)-Cys-]Ala-OH donde P1 y P2 son como se han definido, para dar una pramlintida de cadena lateral protegida de formula (9) P1-Lys(P2)-[Cys-Asn(P2)-Thr(P2)-AIa-Thr(P2)-Cys]-AIa-Thr(P2)-Gln(P2)-Arg(P2)-Leu-AIa-Asn(P2)-Phe-Leu-Val-His(P2)-Ser(P2)-Ser(P2)-Asn(P2)-Asn(P2)-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr(P2)-Asn(P2)-Val-Gly-Ser(P2)-Asn(P2)-Thr(P2)-Tyr(P2)-NH2, (e) desproteger las cadenas laterales y el grupo protector de amino terminal para dar pramlintida (1). Reivindicacion 8: Un péptido de cadena lateral protegida caracterizado porque responde a la formula (3) P1-Thr(P2)-Asn(P2)-Val-Gly-Ser(P2)-Asn(P2)-Thr(P2)-Tyr(P2)-NH2 donde P1 y P2 son grupos protectores.
ARP090103394A 2008-09-03 2009-09-03 Proceso para la preparacion de pramlintida AR073544A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19092808P 2008-09-03 2008-09-03

Publications (1)

Publication Number Publication Date
AR073544A1 true AR073544A1 (es) 2010-11-17

Family

ID=41726391

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090103393A AR073360A1 (es) 2008-09-03 2009-09-03 Proceso para elaborar bivalirudina
ARP090103394A AR073544A1 (es) 2008-09-03 2009-09-03 Proceso para la preparacion de pramlintida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090103393A AR073360A1 (es) 2008-09-03 2009-09-03 Proceso para elaborar bivalirudina

Country Status (11)

Country Link
US (2) US8252896B2 (es)
EP (2) EP2349307B1 (es)
JP (2) JP2012502045A (es)
KR (2) KR20110056536A (es)
CN (2) CN102164609A (es)
AR (2) AR073360A1 (es)
AU (2) AU2009288036A1 (es)
CA (2) CA2736126C (es)
IL (2) IL211556A0 (es)
TW (2) TW201024316A (es)
WO (2) WO2010028131A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1737889T3 (da) 2004-10-19 2011-01-03 Lonza Ag Fremgangsmåde til fastfase-peptidsyntese
AU2008271608A1 (en) * 2007-06-29 2009-01-08 Lonza Ag Process for the production of pramlintide
CA2744627C (en) * 2008-12-29 2016-08-16 Lonza Braine Sa Process for the production of bivalirudin
CN102180943A (zh) * 2010-12-16 2011-09-14 深圳市健元医药科技有限公司 一种辅助降血糖多肽药物的生产工艺
WO2013042129A1 (en) * 2011-09-23 2013-03-28 Natco Pharma Limited Improved process for preparation of bivalirudin
WO2014032257A1 (zh) * 2012-08-30 2014-03-06 深圳翰宇药业股份有限公司 一种比伐卢定的制备方法
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
EP2976325B1 (en) 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of cyclic imide containing peptide products
CN104861045A (zh) * 2014-02-20 2015-08-26 复旦大学 环肽化合物gg6f及其制备方法
ES2939036T3 (es) * 2019-01-24 2023-04-18 Dsm Ip Assets Bv Método de precipitación de péptidos
CN111499719B (zh) * 2020-03-19 2022-04-08 杭州固拓生物科技有限公司 一种合成普兰林肽的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240913A (en) 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
GB9708918D0 (en) 1997-05-01 1997-06-25 Ppl Therapeutics Scotland Ltd Methods
US6821954B2 (en) * 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
WO1999048513A1 (en) * 1998-03-23 1999-09-30 Trimeris, Inc. Methods and compositions for peptide synthesis
DK1737889T3 (da) 2004-10-19 2011-01-03 Lonza Ag Fremgangsmåde til fastfase-peptidsyntese
TW200637872A (en) * 2004-10-26 2006-11-01 Lonza Ag Thiol group protection and cyclization in solid-phase peptide synthesis
EP1805204A2 (en) 2005-09-14 2007-07-11 Novetide Ltd. Process for production of bivalirudin
US20070213505A1 (en) * 2006-03-08 2007-09-13 David Epstein Solution Synthesis of Peptide Cell Growth Stimulators
CN101033249B (zh) 2006-03-10 2011-05-11 周逸明 固相多肽合成比筏芦定的制备方法
WO2008109079A2 (en) 2007-03-01 2008-09-12 Novetide, Ltd. High purity peptides
AU2008271608A1 (en) * 2007-06-29 2009-01-08 Lonza Ag Process for the production of pramlintide
US20090062511A1 (en) 2007-09-05 2009-03-05 Raghavendracharyulu Venkata Palle Process for the preparation of bivalirudin and its pharmaceutical compositions
CA2744627C (en) * 2008-12-29 2016-08-16 Lonza Braine Sa Process for the production of bivalirudin

Also Published As

Publication number Publication date
EP2349307B1 (en) 2015-03-04
JP5788321B2 (ja) 2015-09-30
WO2010028122A8 (en) 2014-11-13
US20100056755A1 (en) 2010-03-04
EP2334314A4 (en) 2012-03-21
WO2010028122A1 (en) 2010-03-11
KR20110056536A (ko) 2011-05-30
AU2009288027B2 (en) 2014-01-16
CN102164608A (zh) 2011-08-24
TW201024316A (en) 2010-07-01
AU2009288027A1 (en) 2010-03-11
CA2736126C (en) 2016-11-29
JP2012502044A (ja) 2012-01-26
AR073360A1 (es) 2010-11-03
TW201014867A (en) 2010-04-16
CA2736126A1 (en) 2010-03-11
US20100081788A1 (en) 2010-04-01
EP2349307A1 (en) 2011-08-03
TWI395752B (zh) 2013-05-11
IL211555A (en) 2014-07-31
WO2010028131A1 (en) 2010-03-11
AU2009288036A2 (en) 2011-09-08
IL211555A0 (en) 2011-05-31
EP2349307A4 (en) 2012-03-21
US8252896B2 (en) 2012-08-28
JP2012502045A (ja) 2012-01-26
AU2009288036A1 (en) 2010-03-11
CA2736113A1 (en) 2010-03-11
EP2334314A1 (en) 2011-06-22
KR101634830B1 (ko) 2016-06-29
AU2009288027A2 (en) 2011-11-03
KR20110069048A (ko) 2011-06-22
IL211556A0 (en) 2011-05-31
CN102164609A (zh) 2011-08-24

Similar Documents

Publication Publication Date Title
AR073544A1 (es) Proceso para la preparacion de pramlintida
PE20121393A1 (es) Analogo peptidico de oxintomodulina
MXPA06001283A (es) Derivados de insulina novedosos.
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
CY1118664T1 (el) Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου
NZ600732A (en) Oxyntomodulin peptide analogue
PE20090108A1 (es) Coagonistas del receptor de glucagon/glp-1
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
WO2013003045A3 (en) Procoagulant peptides and their derivatives and uses therefor
PE20091067A1 (es) Variantes de peptidos natriureticos de tipo c
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
CY1118856T1 (el) Εμβολιο pcsk9
IL188907A0 (en) Protein extracted from plants of the genus lupinus or produced in recombinant form, nucleotide sequence encoding it and its use in animal nutrition, as a plant growth promoter and in the fight against pathogenic fungi
MX2019009377A (es) Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
MY193807A (en) T-cell receptor and uses thereof
MX2023000804A (es) Peptidos para usarse en la promocion del transporte de glucosa.
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
NZ606723A (en) Glatiramer acetate molecular weight markers
AR073810A1 (es) Polipeptidos que tienen actividad antimicrobiana
WO2017211922A3 (en) Protease-resistant mono-lipidated peptides
MX2015001542A (es) Metodo.
NZ600818A (en) Cyclic peptides for the regulation of vectorial ion channels
WO2009105780A3 (en) Mntf peptide compositions and methods of use

Legal Events

Date Code Title Description
FB Suspension of granting procedure